Copy Link Print Information

NRAS Antibody (YA1833)

(Synonyms: NS6; CMNS; NCMS; ALPS4; N-ras; NRAS1)
Customer Review

Based on 1 Customer Validation

NRAS Antibody (YA1833) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NRAS.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, ICC/IF, IP

  • Reactivity :

    Human, Mouse, Rat

  • Formulation:

    Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

  • Conjugation:
    Non-conjugated
  • Experimental Validation Results for NRAS Antibody (YA1833)
  • NRAS Antibody (YA1833) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
Top Publications Citing

Use of MCE Products

Applications

Application
WB Info
WB: Western Blot
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
IP Info
IP: Immunoprecipitation
Dilution Ratio 1:500-1:1000 1:50-1:200 1:20

Product Details

Description

NRAS Antibody (YA1833) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NRAS.

  • Host Rabbit
  • Clonality Recombinant,Monoclonal
  • Species Reactivity
    Human, Mouse, Rat
  • Observed Molecular Weight
    Observed band size: 21 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 21 kDa
Species Reactivity Database
Immunogen

Recombinant protein of human RAS

Sensitivity

Endogenous

Purification

Affinity Purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3104024

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for NRAS Antibody (YA1833)
    Western blot analysis of extracts from Rat brain (lane 2, 20ug), Mouse brain (lane 3, 20ug), Hela (lane 4, 20ug) and NIH/3T3 (lane 5, 20ug) using NRAS Antibody (YA1833) (HY-P82088). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.

Background

  • Function

    N-Ras is a small GTPase that controls cell proliferation, differentiation, and survival through GDP/GTP-regulated signaling[1]. Mechanistically, Ras proteins cycle between ON and OFF states and signal through effector pathways including RAF-MEK-ERK and PI3K[2][3]. In disease models, NRAS has strong relevance in melanoma and acute myelogenous leukemia, and NRAS-mutant melanoma depends on MAPK and PI3K/mTOR signaling[4][5]. Compared with related isoforms, N-Ras, K-Ras, and H-Ras share high G-domain conservation, but biochemical studies show distinct catalytic and signaling properties, so H-Ras data should not be treated as fully representative of N-Ras[1][6]. Isoform distinction also matters experimentally because KRAS is usually more abundant than NRAS in cell-line panels, whereas NRAS often exceeds HRAS in those models[7]. For applications, MEK inhibition with binimetinib improved progression-free survival versus dacarbazine in advanced NRAS-mutant melanoma, while combined MEK and PI3K/mTOR targeting showed antitumor activity in NRAS-mutant melanoma models[8][5]. Recent NRAS-directed monobody work further supports direct inhibition and degradation strategies for NRAS-focused research tools[9].

  • Subcellular Localization

    Cell membrane; Lipid-anchor; Cytoplasmic side; Golgi apparatus membrane; Lipid-anchor

  • Subunit

    Interacts (active GTP-bound form preferentially) with RGS14 (By similarity). Interacts (active GTP-bound form) with RASSF7 (PubMed:21278800). Interacts (active GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:36175670, PubMed:35768504, PubMed:35831509, PubMed:35830882)

  • SwissProt ID

    P01111

  • Gene ID
    4893 [NCBI]
  • Synonyms

    NS6; CMNS; NCMS; ALPS4; N-ras; NRAS1

  • Research Field

    Signal Transduction

References

[1]. Johnson CW, et al. The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects. J Biol Chem. 2017 Aug 4;292(31):12981-12993. [Content Brief]

[2]. Simanshu DK, et al. RAS Proteins and Their Regulators in Human Disease. Cell. 2017 Jun 29;170(1):17-33. [Content Brief]

[3]. Castellano E, et al. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer. 2011 Mar;2(3):261-74. [Content Brief]

[4]. Johnson DB, et al. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res. 2014 Aug 15;20(16):4186-92. [Content Brief]

[5]. Posch C, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. [Content Brief]

[6]. Castellano E, et al. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011 Mar;2(3):216-31. [Content Brief]

[7]. Hood FE, et al. Ras protein abundance correlates with Ras isoform mutation patterns in cancer. Oncogene. 2023 Apr;42(15):1224-1232. [Content Brief]

[8]. Dummer R, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. [Content Brief]

[9]. Whaby M, et al. Inhibition and degradation of NRAS with a pan-NRAS monobody. Oncogene. 2024 Nov;43(48):3489-3497. [Content Brief]

View More

NRAS Antibody (YA1833) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     Western blot analysis of extracts from Rat brain (lane 2, 20ug), Mouse brain (lane 3, 20ug), Hela (lane 4, 20ug) and NIH/3T3 (lane 5, 20ug) using NRAS Antibody (YA1833) (HY-P82088). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.

  • NRAS Antibody (YA1833) Product Image
    1/16
  • Experimental Validation Results for NRAS Antibody (YA1833)
  • NRAS Antibody (YA1833) Product Image
  • Experimental Validation Results for NRAS Antibody (YA1833)
    1/1
    MedChemExpress Validation
     Western blot analysis of extracts from Rat brain (lane 2, 20ug), Mouse brain (lane 3, 20ug), Hela (lane 4, 20ug) and NIH/3T3 (lane 5, 20ug) using NRAS Antibody (YA1833) (HY-P82088). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.
  • Experimental Validation Results for NRAS Antibody (YA1833)
  • NRAS Antibody (YA1833) Product Image
    MedChemExpress Validation

    Western blot analysis of extracts from Rat brain (lane 2, 20ug), Mouse brain (lane 3, 20ug), Hela (lane 4, 20ug) and NIH/3T3 (lane 5, 20ug) using NRAS Antibody (YA1833) (HY-P82088). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.

  • NRAS Antibody (YA1833) Product Image WB